Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
Completed
- Conditions
- Multiple Myeloma
- Registration Number
- NCT03276481
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 47
Inclusion Criteria
- Age 21 or above with diagnosis of multiple myeloma (myeloma is almost unheard of in patients less than 21 years of age).
- Scheduled to receive conditioning chemotherapy with melphalan followed by upfront or salvage autologous peripheral blood hematopoietic stem cell transplantation
- English or Spanish speaking
- Calculated creatinine clearance > 40 mL/min
Exclusion Criteria
- Prior head and neck radiation.
- Severe periodontal infection. Poor oral hygiene and dentition as determined by pre HCT dental assessment.
- Pregnancy
- Patients with pre-existing moderate-severe dysgeusia
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility of comprehensive chemical gustometry in participants with multiple myeloma undergoing autologous HCT Change from baseline assessment up to 100 days The primary objective of this protocol is to evaluate the feasibility of comprehensive chemical gustometry in participants with MM undergoing autologous HCT. Chemical gustometry will be evaluated at baseline and on days -1, 7, 14, 30 and 100.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center🇺🇸New York, New York, United States